VivoSeq
Oncology

Hepatocellular Carcinoma (HCC)

6

Pipeline Programs↗

12

Active Trials↗

3

Companies Involved↗

Hepatocellular Carcinoma (HCC) is an early-stage landscape with 6 programs across 3 companies. The most active players are AstraZeneca, Viatris Specialty LLC, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

30/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Monoclonal antibody

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule233%

Monoclonal antibody leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

15

clinical trials

Recruiting7 · 47%
Not yet recruiting4 · 27%
Completed3 · 20%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Recruiting·CCity of Hope Medical Center·N/A·NCT07224750·1,000 enrolled
CHOC - Implementation and Evaluation of an Ambulatory Care Pathway for Intra-arterial Treatment of Primary Liver Cancer: Study Protocol for a Multicentre Randomised Controlled Hybrid Type 1 Trial Implémentation et évaluation d'un Parcours de Soin Ambulatoire Pour Les Patients traités Par Voie Intra-artérielle d'un Cancer Primitif du Foie : Essai Multicentrique contrôlé randomisé
Recruiting·UUniversity Hospital, Angers·Preclinical·NCT06990659·206 enrolled
Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma
Recruiting·TThe First Affiliated Hospital of Xiamen University·Preclinical·NCT07677774·40 enrolled
Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)
Recruiting·CCity of Hope Medical Center·N/A·NCT07265271·600 enrolled
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT07291076·198 enrolled
Addition of F18-Piflufolastat PET/CT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma
Recruiting·VVA Office of Research and Development·N/A·NCT07019844·90 enrolled
Study of the Safety, Clinical Efficacy and Prognostic Factors of TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT07658833·120 enrolled
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06040099·58 enrolled
Phase 2 Trial of Adaptive Dosing of Immune Checkpoint Inhibitors for Unresectable Child Pugh B Hepatocellular Carcinoma
Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT07689175·60 enrolled
Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Not yet recruiting·UUniversity of California, San Francisco·Phase 2·NCT07682454·50 enrolled
A Prospective, Multicenter, Open-label Two Cohort Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.
Not yet recruiting·SSirtex Medical·Phase 2·NCT07663487·78 enrolled
A Post Approval Single-arm Study Evaluating Transarterial Radioembolization Treatment for Hepatocellular Carcinoma Using Multicompartment Dosimetry Planning
Not yet recruiting·BBoston Scientific Corporation·N/A·NCT07669727·140 enrolled
First Line Hepato Cellular Carcinoma (HCC)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT00858871·1,714 enrolled
Multimodal Hybrid Deep Learning-based Prognostic Decision System to Guide Adjuvant Therapy in Hepatocellular Carcinoma After Surgical Resection
Completed·AAnhui Provincial Hospital·N/A·NCT07700082·555 enrolled
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Completed·AAnhui Provincial Hospital·N/A·NCT07562763·1,005 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)